纤连蛋白(FN)雾化吸入治疗COVID-19的临床效果观察

Clinical observation of COVID-19 treated with fibronectin(FN)inhalation

目的观察纤连蛋白(FN)雾化吸入治疗新型冠状病毒肺炎(COVID-19)的临床效果。方法对武汉华中科技大学同济医学院附属协和医院西院神经科病房48例COVID-19患者分别给予纤连蛋白皮肤抑菌液雾化吸入治疗。雾化吸入纤连蛋白7~14 d,每日给予两次雾化,每次雾化液约15 mL,雾化给药时长为10~15 min。结果经雾化吸入纤连蛋白7~14 d后,患者呼吸困难减轻、咳嗽减轻、咳痰减轻、肺部渗出液减少、排痰顺畅、肺部CT影像病灶减少。结论纤连蛋白雾化吸入治疗新型冠状病毒肺炎有一定效果。

Objective To observe the clinical effect of COVID-19 treated with fibronectin inhalation.MethodsForty-eight COVID-19 patients in Department of Neurology,Xiehe Hospital,Tongji Medical College,Wuhan Huazhong University of Science and Technology,were treated with aerosol inhalation of fibronectin skin antibacterial liquid,respectively.Aerosol inhalation of fibronectin for 7-14 days was given twice a day,about 15 mL of aerosol solution each time.The duration of aerosol administration was 10-15 minutes.Results After inhalation of fibronectin for 7-14 days,the patients were given atomization twice a day,and each time the atomization liquid was about 15 mL,the clinical manifestations of patients showed that dyspnea improved,cough reduction,sputum reduction,pulmonary exudate reduction,sputum smooth and CT imaging lesions decreased.Conclusions Inhalation of fibronectin is effective for the treatment of COVID-19 infection.